Hutchmed (China) Limited

Major Shareholding Notification • Dec 20, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3267S

Hutchison China Meditech Limited

20 December 2016

Director's Share Dealing

London: Tuesday, December 20, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Mr Simon To, Executive Director and Chairman, purchased a total of 17,839 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med ("Ordinary Share")) at an average price of US$14.45 per ADS on December 15, 2016 and December 16, 2016. 

Following the above purchase of 17,839 ADSs, Mr To is interested in 70,000 ADSs and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in a family trust of which his family members are the beneficiaries), representing approximately 0.35% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation. 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Mr Simon To

2

Reason for the notification

a)

Position/status

Executive Director and Chairman

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hutchison China MediTech Limited

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing one half of one Ordinary Share of US$1.00

ADS ISIN: US44842L1035

b)

Nature of the transaction

Acquisition of ADSs

c)

Price(s) and volume(s)

Price(s)	Volume(s)
US$14.47	8,552

d)

Aggregated information

-	Aggregated volume
-	Price

N/A

e)

Date of the transaction

2016-12-15

f)

Place of the transaction

Nasdaq Stock Market

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing one half of one Ordinary Share of US$1.00

ADS ISIN: US44842L1035

b)

Nature of the transaction

Acquisition of ADSs

c)

Price(s) and volume(s)

Price(s)	Volume(s)
US$14.43	9,287

d)

Aggregated information

-	Aggregated volume
-	Price

N/A

e)

Date of the transaction

2016-12-16

f)

Place of the transaction

Nasdaq Stock Market

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries
Christian Hogg, CEO	+852 2121 8200
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson	+44 7973 611 888 (Mobile)	[email protected]
U.S. Based Media Enquiries
Brad Miles, BMC Communications	+1 (917) 570 7340 (Mobile)	[email protected]
Susan Duffy, BMC Communications	+1 (917) 499 8887 (Mobile)	[email protected]
Investor Relations
Matt Beck, The Trout Group	+1 (917) 415 1750 (Mobile)	[email protected]
David Dible, Citigate Dewe Rogerson	+44 7967 566 919 (Mobile)	[email protected]
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts	+44 (20) 7886 2500

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLIFLDFELIFIR